Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (June 2023)
20 slides from Botanix Pharmaceuticals's investor presentation, Jun 7, 2023
Slide 1: Investor Webinar Presentation
7 June 2023 Investor Webinar Presentation Philadelphia and Phoenix US, 7 June 2023: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to provide a copy of its investor presentation as attached to this release. Release authorised by Vince
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “pla
Slide 3: Investor Webinar June 2023
For personal use only Investor Webinar June 2023 www.botanixpharma.com
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer 1. Summary information This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise
Slide 5: Executing on planned commercial and regulatory milestones
Executing on planned commercial and regulatory milestones For personal use only CALENDAR YEAR NDA DAY 74 MID-CYCLE LABEL FDA SUBMISSION LETTER REVIEW NEGOTIATION APPROVAL COMPLETE ✔ ✔ ✔ 3Q 2022 DECEMBER 2022 1Q 2023 2Q 2023 SEP 2023 3 www.botanixpharma.com
Slide 6: Activities leading up to FDA approval
Activities leading up to FDA approval Ini>a>on of label nego>a>ons accelerates Botanix’s commercial ac>vi>es ready for launch For personal use only v Planned to commence late Q2 2023 to be finalized LABEL NEGOTIATIONS before anticipated approval in Q3 2023 COMMERCIAL MANUFACTURING & v Finalizing the
Slide 7: Label negotiations
Label nego:a:ons Towards the end of the NDA review process, FDA and Botanix nego>ate the drug’s final package label For personal use only v The label will reflect the efficacy and safety data that FDA and EFFICACY AND SAFETY DATA the Sponsor (Botanix) agrees needs to be included v The label provides
Slide 8: Commercial manufacturing and packaging
Commercial manufacturing and packaging Utilizing same site as Phase 3 studies and at same scale and equipment For personal use only v Well-characterised synthetic process - room temperature stability >36 months DRUG SUBSTANCE (API) v Manufactured by same company as for our partner Kaken in Japan (at
Slide 9: Efficient dermatologist targeting plus digital strategy expands the addressable patient population
Efficient dermatologist targe:ng plus digital strategy—expands the addressable pa:ent popula:on For personal use only US Hyperhidrosis Population ~336M Hyperhidrosis Pa.ents ~16.1M Poten#al to diagnose and treat Axillary Hyperhidrosis from home with telemedicine ~10M Pa.ents Pa#ents already in dermato
Slide 10: Hyperhidrosis: Significant Unmet Medical Need
Hyperhidrosis: Significant Unmet Medical Need When provided with a selection of key dermatologic indications, surveyed clinicians ranked hyperhidrosis last in their ability to successfully manage with available treatment options For personal use only RANKING OF ABILITY TO SUCCESSFULLY MANAGE WITH AV
Slide 11: SB Gel launch strategy
SB Gel launch strategy Rapidly establish SB Gel as a safe and effec>ve first-line topical treatment of For personal use only primary axillary hyperhidrosis, in pa>ents 9 years of age and older Drive dermatology adoption through comprehensive engagement around a compelling clinical story Engage and mot
Slide 12: Drive adoption: create tools to drive early adoption
DRIVE ADOPTION Create tools to drive early adop:on Targeted at dermatologists and patients For personal use only v CreaQve v Sales force leave behind v Messaging v Sales force objecQon handler v Logo v Sales force generated emails v Carton v Journal adverQsement v Brand website v Clinical reprint v
Slide 13: Engage & motivate: consumer collateral
ENGAGE & MOTIVATE Create consumer collateral to engage and mo:vate pa:ents Targeted at dermatologists and patients For personal use only v Consumer creaQve v PaQent advocacy plan v Consumer messaging v Public relaQons plan v Branded banners ads v Consumer medical plan v Consumer website – SEO/SEM v
Slide 14: Maximize coverage: implement insurance (payer) plans
MAXIMIZE COVERAGE Implement insurance (payer) plans For personal use only PAYER VALUE v Compelling payer value proposi8on, leveraging market research/internal exper8se PROPOSITION & KEY v Tools and resources to effec8vely communicate value proposi8on COMMUNICATIONS v Communicate key product info to p
Slide 15: Provide access: pharmacy network connected to telemedicine provider
Create a pharmacy network that is directly connected to a PROVIDE ACCESS telemedicine provider, that will facilitate prescribing of SB Gel PROPOSED PROGRAM DESIGN For personal use only Remove barriers to use by providing doctors with the ability to prescribe SB Gel at launch CONSIGNED PRODUCT TELEME
Slide 16: Provide access: finalize contracts with partners
PROVIDE ACCESS Finalize contracts with partners that meet key criteria Discussions underway For personal use only Telemedicine Partner Pharmacy Partner v History of experience v Fulfillment in all 50 states v Prescribing in all 50 states v Coordinates central filling to optimize data v Exceeds indus
Slide 17: Train sales force
TRAIN SALES FORCE Rapid scale up of sales force aPer FDA approval For personal use only SALES FORCE ONBOARDING & Comprehensive, pressure-tested, TRAINING PLAN onboarding and training plan anchored to the key field activities v Rapid scale-up of a 20–30 rep that we initially target field force v Effi
Slide 18: Why we're excited about the Sofpironium Bromide opportunity
Why we’re excited about the Sofpironium Bromide opportunity Significant Market PotenPal Robust Launched in Global For personal use only Opportunity Best-in-Class Clinical Data Japan IP Protection v Hyperhidrosis (HH) v New chemical entity v Positive and v SB gel, 5% (ECCLOCK®) v Comprehensive IP in i
Slide 19: Executing on planned commercial and regulatory milestones
Executing on planned commercial and regulatory milestones For personal use only CALENDAR YEAR NDA DAY 74 MID-CYCLE LABEL FDA SUBMISSION LETTER REVIEW NEGOTIATION APPROVAL COMPLETE ✔ ✔ ✔ 3Q 2022 DECEMBER 2022 1Q 2023 2Q 2023 SEP 2023 17 www.botanixpharma.com
Slide 20: For personal use only
For personal use only www.botanixpharma.com
Botanix Pharmaceuticals — Investor Presentation (June 2023) on 6ix